Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study

European Journal of Clinical Pharmacology

Volumn 51, Issue 5, 1997, Pages 395-398

  Spina, E ^a,b   Gitto, C ^b   Avenoso, A ^a   Campo, G M ^a   Caputi, A P ^a   Perucca, E ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b USL 5   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

CYP2D6; Desipramine; Dextromethorhan; Phenotyping

Indexed keywords

2 HYDROXYDESIPRAMINE; DESIPRAMINE; DRUG METABOLITE;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; DESIPRAMINE; DEXTROMETHORPHAN; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 0031028101     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050220     Document Type: Article

References (23)

1. Dahl ML, Bertilsson L (1993) Genetically variable metabolism of antidepressants and neuroleptic drug in man. Pharmacogenetics 3: 61-70
2. Spina E, Caputi AP (1994) Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications. Pharmacol Res 29: 121-137
3. Bertilsson L, Dahl ML (1996) Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 5: 200-223
4. Bertilsson L, Aberg-Wistedt A (1983) The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 15: 388-390
5. Nordin C, Siwers B, Benitez J, Bertilsson L (1985) Plasma concentrations of nortriptyline and its 10-hydroxymetabolite in depressed patients: relation to polymorphic debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol 19: 832-835
6. Brosen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L (1986) Steady-state concentrations of imipramine and its metabolities in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 30: 679-684
7. Spina E, Arena A, Pisani F (1987) Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine. Ther Drug Monit 9: 129-133
8. Bertilsson L, Mellstrom B, Sjoqvist F, Martensson B, Asberg M (1981) Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet i: 560-561
9. Bertilsson L, Aberg-Wistedt A, Gustaffson LL, Nordin C (1985) Extremely rapid hydroxylation of debrisoquine: a case report with implicaton for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7: 478-480
10. Bluhm RE, Wilkinson GR, Shelton R, Branch RA (1993) Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. Clin Pharmacol Ther 53: 89-95
11. Meyer JW, Woggon B, Kupfer A (1988) Importance of oxidative polymorphism on clinical efficacy and side-effects of imipramine: a retrospective study. Pharmacopsychiatry 21: 365-366
12. Spina E, Steiner E, Ericsson O, Sjoqvist F (1987) Hydroxylation of desmethylimipramine: dependence on the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 41: 314-319
13. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278-296
14. Spina E, Campo GM, Avenoso A, Caputi AP, Zuccaro P, Pacific R, Gatti G, Strada G, Bartoli A, Perucca E (1994) CYP2D6-related oxidation polymorphism in Italy. Pharmacol Res 29: 281-289
15. Silverman G, Braithwaite RA (1973) Benzodiazepines and tricyclic antidepressant plasma levels. BMJ 3: 18-20
16. Sutfin TA, Jusko WJ (1979) High-performance liquid chromatography assay for imipramine, desipramine, and their 2-hydroxylated metabolites. J Pharm Sci 68: 703-705
17. Reisby N, Gram LF, Bech P, Nagy A, Petersen GO, Ortmann J, Ibsen I, Deneker SJ, Jacobsen O, Krautwald O, Sondergaard I, Christiansen J (1977) Imipramine: clinical effects and pharmacokinetic variability. Psychopharmacology 54: 263-272
18. Classman A, Perel JM, Shostak M, Kantor SJ, Fleiss JL (1977) Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 34: 197-204
19. Asberg M, Cronholm B, Sjoqvist F, Tuck D (1971) Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 3: 331-334
20. Nelson JC, Jatlow P, Quinlan DM, Bowers MB (1982) Desipramine plasma concentration and antidepressant response. Arch Gen Psychiatry 39: 1419-1422
21. Amsterdam JD, Brunswick DJ, Potter L, Winokur A, Rickels K (1985) Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients: lack of correlation with therapeutic response. Arch Gen Psychiatry 42: 361-364
22. Potter WZ, Calil HM, Sutfin TA, Zavadil AP, Jusko WJ, Rapoport J, Goodwin FK (1982) Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther 32: 393-401
23. Bertilsson L, Dahl ML, Sjoqvist F, Aberg-Wistedt A, Humble M, Johannson I, Lundqvist E, Ingelman-Sundberg M (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators for debrisoquine. Lancet 341: 63